Although CA IT did not much improve the efficacy of nivolumab in NSQ-NSCLC with PD-L1 expression < 10%, two patients showed dramatic and durable responses with decreasing MDSC, which contributed to poor outcomes with immunotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.